The company was established in February 1997 with the approval of Su Zhengfu [1997] Document No. 19 of the Jiangsu Provincial People's Government, and is a limited company co-sponsored by five founders including Jiangsu Hengrui Group Co., Ltd. (formerly Lianyungang Pharmaceutical Industry Company) and China Pharmaceutical Industry Corporation. The company registered on April 28, 1997 and received a business license issued by the Lianyungang Administration for Industry and Commerce. The unified social credit code is 9132070070404786XB. The company's main business involves R&D, production and sales of pharmaceuticals. Main products: A wide range of research fields such as kinase inhibitors, antibody conjugated drugs (ADCs), tumor immunity, hormone receptor regulation, DNA repair and epigenetics, and supportive therapy. The company was selected by the China Pharmaceutical Enterprise Management Association as “2018 China Pharmaceutical Listed Companies R&D Innovation Top 10”, and won many honors such as “2018 China Chemical Pharmaceutical Industry Top 100 Industrial Enterprises Comprehensive Strength” and “2018 China Chemical and Pharmaceutical Industry Innovative Excellent Enterprise Brand” at the 2018 China Chemical and Pharmaceutical Industry Annual Summit.
No Data